Tretinoin is a retinoid sold in the U.S. under 7 brand and generic names, for acne vulgaris, facial dermatoses and acute promyelocytic leukemia. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Tretinoin (application ANDA218245). Other tretinoin products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Tretinoin gel should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Excessive application results in “pilling” of the gel, which minimizes the likelihood of overapplication by the patient. Application may cause a transitory feeling of warmth or slight stinging. In cases where it has been necessary to temporarily discontinue therapy or to reduce the frequency of application, therapy may be resumed or frequency of application increased when the patients become able to tolerate the treatment. Alterations of vehicle, drug concentration, or dose frequency should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. During the early weeks of therapy, an apparent exacerbation of inflammatory lesions may occur. This is due to the action of the medication on deep, previously unseen lesions and should not be considered a reason to discontinue therapy. Therapeutic results should be noticed after 2 to 3 weeks but more than 6 weeks of therapy may be required before definite beneficial effects are seen. Once the acne lesions have responded satisfactorily, it may be possible to maintain the improvement with less frequent applications, or other dosage forms. Patients treated with tretinoin gel acne treatment may use cosmetics, but the area to be treated should…
The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication should be adjusted to a level the patient can tolerate. True contact allergy to topical tretinoin is rarely encountered. Temporary hyper- or hypopigmentation has been reported with repeated application of tretinoin. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with tretinoin. To date, all adverse effects of tretinoin have been reversible upon discontinuance of therapy (see DOSAGE AND ADMINISTRATION ). To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Topical | Generic | $1 | View → | |
| 2 | 70/100 | Prescription | Topical | Generic |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| R135 | 10 mg | blue | oval | — |
| R136 | 20 mg | pink | oval | — |
| RI | 30 mg | red | oval | — |
| R137 | 40 mg | green | oval | — |
| 570 | 10 mg | yellow | oval | — |
| 571 | 20 mg | pink |
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Claravis (isotretinoin capsule
Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin
Teva Pharmaceuticals USA, Inc · Apr 6, 2026
Amnesteem (Isotretinoin) Capsules
Failed Dissolution Specifications
MYLAN PHARMACEUTICALS INC · Feb 24, 2026
Isotretinoin Capsules
Superpotent and Subpotent
Teva Pharmaceuticals USA, Inc · Jan 12, 2026
Isotretinoin Capsules
Superpotent and Subpotent
Teva Pharmaceuticals USA, Inc · Jan 12, 2026
Isotretinoin Capsules
Superpotent Drug: The 3-month stability result for assay was found to be above specification limit
Teva Pharmaceuticals USA, Inc · Mar 28, 2024
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.
Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin. Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin. It also is advisable to “rest” a patient’s skin until the effects of such preparations subside before use of tretinoin is begun.
| $1 |
| View → |
| 3 | 64/100 | Prescription | Capsule | Generic | $1 | View → |
| 4 | Not yet rated | Prescription | Topical | Generic | $1 | View → |
| 5 | Not yet rated | Prescription | Topical | Generic | $1 | View → |
| 6 | Not yet rated | Prescription | Topical | Generic | $1 | View → |
| 7 | Not yet rated | Prescription | Capsule | Generic | $1 | View → |
| oval |
| — |
| 573 | 30 mg | brown | oval | — |
|---|
| V10 | 10 mg | yellow | capsule | — |
|---|
| V20 | 20 mg | pink | capsule | — |
|---|
| V30 | 30 mg | pink | capsule | — |
|---|
| V40 | 40 mg | orange | capsule | — |
|---|
| J1 | 10 mg | blue | oval | — |
|---|